Danish Headache Center, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark.
CNS Drugs. 2012 Jul 1;26(7):571-80. doi: 10.2165/11632850-000000000-00000.
The prevalence of cluster headache is 0.1% and cluster headache is often not diagnosed or misdiagnosed as migraine or sinusitis. In cluster headache there is often a considerable diagnostic delay - an average of 7 years in a population-based survey. Cluster headache is characterized by very severe or severe orbital or periorbital pain with a duration of 15-180 minutes. The cluster headache attacks are accompanied by characteristic associated unilateral symptoms such as tearing, nasal congestion and/or rhinorrhoea, eyelid oedema, miosis and/or ptosis. In addition, there is a sense of restlessness and agitation. Patients may have up to eight attacks per day. Episodic cluster headache (ECH) occurs in clusters of weeks to months duration, whereas chronic cluster headache (CCH) attacks occur for more than 1 year without remissions. Management of cluster headache is divided into acute attack treatment and prophylactic treatment. In ECH and CCH the attacks can be treated with oxygen (12 L/min) or subcutaneous sumatriptan 6 mg. For both oxygen and sumatriptan there are two randomized, placebo-controlled trials demonstrating efficacy. In both ECH and CCH, verapamil is the prophylactic drug of choice. Verapamil 360 mg/day was found to be superior to placebo in one clinical trial. In clinical practice, daily doses of 480-720 mg are mostly used. Thus, the dose of verapamil used in cluster headache treatment may be double the dose used in cardiology, and with the higher doses the PR interval should be checked with an ECG. At the start of a cluster, transitional preventive treatment such as corticosteroids or greater occipital nerve blockade can be given. In CCH and in long-standing clusters of ECH, lithium, methysergide, topiramate, valproic acid and ergotamine tartrate can be used as add-on prophylactic treatment. In drug-resistant CCH, neuromodulation with either occipital nerve stimulation or deep brain stimulation of the hypothalamus is an alternative treatment strategy. For most cluster headache patients there are fairly good treatment options both for acute attacks and for prophylaxis. The big problem is the diagnosis of cluster headache as demonstrated by the diagnostic delay of 7 years. However, the relatively short-lasting attack of pain in one eye with typical associated symptoms should lead the family doctor to suspect cluster headache resulting in a referral to a neurologist or a headache centre with experience in the treatment of cluster headache.
丛集性头痛的患病率为 0.1%,常被误诊为偏头痛或鼻窦炎。在丛集性头痛中,往往存在相当长的诊断延迟——在一项基于人群的调查中,平均为 7 年。丛集性头痛的特征是非常严重或严重的眶周或眶周疼痛,持续时间为 15-180 分钟。丛集性头痛发作伴有特征性的单侧症状,如流泪、鼻塞和/或鼻漏、眼睑水肿、瞳孔缩小和/或上睑下垂。此外,还会出现不安和激动。患者每天可能发作多达 8 次。发作性丛集性头痛(ECH)发生在数周至数月的丛集期,而慢性丛集性头痛(CCH)发作持续 1 年以上,无缓解期。丛集性头痛的治疗分为急性发作治疗和预防性治疗。在 ECH 和 CCH 中,发作可以用氧气(12 L/min)或皮下舒马曲坦 6mg 治疗。对于氧气和舒马曲坦,都有两项随机、安慰剂对照试验证明了其疗效。在 ECH 和 CCH 中,维拉帕米是首选的预防药物。一项临床试验发现,维拉帕米 360mg/天优于安慰剂。在临床实践中,大多使用每天 480-720mg 的剂量。因此,用于治疗丛集性头痛的维拉帕米剂量可能是心内科剂量的两倍,并且随着剂量的增加,应该用心电图检查 PR 间期。在丛集性头痛开始时,可以给予过渡性预防治疗,如皮质类固醇或枕大神经阻滞。在 CCH 和 ECH 长期发作中,可以使用锂、麦角乙脲、托吡酯、丙戊酸和酒石酸麦角胺作为附加预防治疗。对于耐药性 CCH,神经调节,即枕大神经刺激或下丘脑深部脑刺激,是一种替代治疗策略。对于大多数丛集性头痛患者,无论是急性发作还是预防治疗,都有相当好的治疗选择。最大的问题是丛集性头痛的诊断,如 7 年的诊断延迟所示。然而,一只眼睛的疼痛发作相对短暂,伴有典型的相关症状,这应该让家庭医生怀疑是丛集性头痛,并将其转介给治疗丛集性头痛有经验的神经科医生或头痛中心。